| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/03/2025 | 22:57 | Edgar (US Regulatory) | Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 04/03/2025 | 22:52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 27/02/2025 | 22:52 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 27/02/2025 | 22:46 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 27/02/2025 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 18/02/2025 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 06/02/2025 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 31/01/2025 | 23:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 31/10/2024 | 13:00 | GlobeNewswire Inc. | Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/10/2024 | 13:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 29/10/2024 | 21:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 29/10/2024 | 13:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Third Quarter 2024 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 08/10/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 17/09/2024 | 22:40 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 17/09/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 14/08/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/07/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Second Quarter 2024 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 09/07/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 23/05/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/04/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports First Quarter 2024 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 11/04/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 07/03/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 06/03/2024 | 22:39 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 13:25 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 22/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 07/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/11/2023 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 01/11/2023 | 13:05 | GlobeNewswire Inc. | Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 31/10/2023 | 13:05 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Third Quarter 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
